P
Pentixapharm
Improving the life of patients with malignant diseases through targeted molecular diagnostic and therapy based on innovative nuclear medicine
About Pentixapharm
Pentixapharm, established in 2019 and headquartered in Germany, specializes in the development of radiopharmaceuticals focusing on CXCR4 ligand-based approaches. The company targets both diagnostic and therapeutic applications across a range of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. By utilizing a theranostic mode of action, Pentixapharm's solutions enable specific binding of ligands to pathological cell structures, facilitating both diagnosis and therapy. The business model revolves around the development and commercialization of these radiopharmaceuticals, with revenue generated through partnerships, licensing, and direct sales. Pentixapharm recently completed a successful spin-off from the Eckert Ziegler Group, culminating in its listing on the Frankfurt Stock Exchange. The company serves healthcare providers and research institutions, operating within the radiopharmaceutical sector. Key opportunities for investors include the company's innovative pipeline and its strategic positioning in the growing market for targeted cancer therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2019
- Headquarters
- Berlin, Germany
- Listing
- IPO 2024
- Employees
- 37
- Open positions
- 2
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2026 | $22M | — | Undisclosed | ↗ |
| IPO✓Exit | Oct 2024 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Pentixapharm is 2.1K monthly website visits, up 5% over the last three months. Pentixapharm's team declined 26% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Eckert Life Science Accelerator
Series B and later1 investor entered at this stage
Eckert & Ziegler Bebig SA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pentixapharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pentixapharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.